Evidence map›Paper›PMID 27510839›Full record

ArticleMolecular medicine reports2016

Hypolipidemic effects of HVC1 in a high cholesterol diet‑induced rat model of hyperlipidemia.

Chae-Yun Kim, Kyung-Sook Chung, Se-Yun Cheon, Kyungjin Lee, Inhye Ham, Ho-Young Choi, Yong Baik Cho, Byoung-Heon Cho, So Youn Mok, Hyo-Jin An

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Pharmacological effects ofPharmaceutical biology · 2022
    Article
  2. Article
  3. Article
  4. Thirteen-Week Oral Toxicity Study of HVC1 in Rats.Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chae-Yun KimDepartment of Pharmacology, College of Oriental Medicine, Sangji University, Wonju, Gangwon‑do 220702, Republic of Korea.
Kyung-Sook ChungDepartment of Pharmacology, College of Oriental Medicine, Sangji University, Wonju, Gangwon‑do 220702, Republic of Korea.
Se-Yun CheonDepartment of Pharmacology, College of Oriental Medicine, Sangji University, Wonju, Gangwon‑do 220702, Republic of Korea.
Kyungjin LeeDepartment of Herbology, College of Korean Medicine, Kyung Hee University, Seoul 130701, Republic of Korea.
Inhye HamDepartment of Herbology, College of Korean Medicine, Kyung Hee University, Seoul 130701, Republic of Korea.
Ho-Young ChoiDepartment of Herbology, College of Korean Medicine, Kyung Hee University, Seoul 130701, Republic of Korea.
Yong Baik ChoPharmaceutical R&D Center, Kolmar Korea Co. Ltd, Sejong 339853, Republic of Korea.
Byoung-Heon ChoPharmaceutical R&D Center, Kolmar Korea Co. Ltd, Sejong 339853, Republic of Korea.
So Youn MokPharmaceutical R&D Center, Kolmar Korea Co. Ltd, Sejong 339853, Republic of Korea.
Hyo-Jin AnDepartment of Pharmacology, College of Oriental Medicine, Sangji University, Wonju, Gangwon‑do 220702, Republic of Korea.
Sangji University · KRKolmar Korea (South Korea) · KRKyung Hee University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HVC1, a novel formation containing four herbs, was developed and its hypolipidemic effects in rats with high cholesterol diet (HCD)‑induced hyperlipidemia were investigated. The rats were given a HCD for 8 weeks. The HVC1‑treated groups were orally administered HVC1 at doses of 10, 50 or 250 mg/kg, respectively, and the simvastatin group was treated at a dose of 10 mg/kg. The normal diet and HCD control groups were administered with physiological saline. Oral administration of HVC1 (10, 50 or 250 mg/kg) significantly reduced the body weight of rats with hyperlipidemia and regulated the total cholesterol, low‑density lipoprotein cholesterol and high‑density lipoprotein cholesterol levels in the serum. In addition, tissue analysis revealed that lipid accumulation in the liver and aorta was reduced by HVC1 administration. Furthermore, HVC1 significantly reduced the mRNA expression of peroxisome proliferator‑activated receptor‑γ, 3‑hydroxy‑3‑methylglutaryl‑CoA reductase and low‑density lipoprotein receptor, as well as the protein level of 5' adenosine monophosphate‑activated protein kinase in the liver. The results clearly demonstrate that HVC1 has a potent hypolipidemic effect, and suggest that HVC1 should be evaluated as a potential treatment for hyperlipidemia.

Indexed as

Medicine, Korean TraditionalAnimalsAortaCholesterolDiet, High-FatGene Expression RegulationHyperlipidemiasHypolipidemic AgentsLipid MetabolismLiverMalePlant ExtractsPlants, MedicinalPolygonaceaePPAR gammaRanunculaceaeCholesterolHypolipidemic AgentsPlant ExtractsPPAR gammaReceptors, LDLRNA, Messenger

Identifiers

PMID27510839
PMCPMC5042765
OpenAlexW2507582491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.